Alfica Sehgal, Judo Bio CSO
October 7, 2024 07:00 AM EDT
R&D

Ju­do Bio launch­es with $100M for kid­ney-tar­get­ed siR­NA ther­a­pies

Ryan Cross

Senior Science Correspondent

The kid­ney hasn’t al­ways got­ten much love from ge­net­ic med­i­cine.
The or­gan is vi­tal to our health, but is of­ten viewed as a li­a­bil­i­ty for …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

David Ep­stein gets $140M for Ot­ti­mo's bi­func­tion­al take on hot PD-1xVEGF field

A service from the Financial Times